Maze Therapeutics Launches with USD 191m to Focus on Translating Genetic Insights into New Medicines.
(C)2019 M2 COMMUNICATIONS
- US-based healthcare venture firm Third Rock Ventures has led the launch of Maze Therapeutics, a company focused on translating genetic insights into new medicines, the firm said.
The company has secured an initial investment commitment of USD 191m, led by Third Rock Ventures and ARCH Venture Partners, with participation from GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and other undisclosed investors.
In recent years, the amount of genetic data has grown exponentially, leading to a better understanding of how certain mutations in genes cause disease.
However, it is unclear why some people with mutations expected to cause severe disease display only mild symptoms, or - in extreme cases - are not affected at all.
Often this is due to genes elsewhere in their DNA that impact the severity of disease and can provide a natural form of protection. These genes are known as genetic modifiers.
Maze has brought together a group of world scientific founders who are experts in their respective fields.
Mark Daly, Ph.D., a pioneer in the field of human genetics. Dr. Daly is a co-director of the Program in Medical and Population Genetics at the Broad Institute, founding chief of the Analytic and Translational Genetics Unit at Massachusetts General Hospital, and director of the Institute for Molecular Medicine Finland.
Stephen Elledge, Ph.D., a leader in the field of genetics. Dr. Elledge is the Gregor Mendel Professor of Genetics and Medicine at Harvard Medical School and Brigham and Women's Hospital; an investigator at the Howard Hughes Medical Institute; and is a recipient of the Lasker Award, Gairdner International Award and The Breakthrough Prize in Life Sciences.
Aaron Gitler, Ph.D., a neuroscientist and genetics expert whose work has focused on understanding the cellular consequences of protein misfolding to suggest potential strategies for therapeutic intervention. Dr. Gitler is a professor of genetics at Stanford University.
Sekar Kathiresan, M.D., a renowned physician-scientist and human geneticist who is focused on the genetics of complex diseases. Dr. Kathiresan is director of the Center for Genomic Medicine at Massachusetts General Hospital; director of the Cardiovascular Disease Initiative at the Broad Institute; and professor of medicine at Harvard Medical School.
Jonathan Weissman, Ph.D., widely recognized for building innovative tools to interrogate the organizational principals of biological systems. He is a professor and vice chair of the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco and investigator at the Howard Hughes Medical Institute.
The Maze leadership team is comprised of industry leading scientists and company builders. Joining CEO Dr. Homcy are Tim Behrens, M.D., senior vice president, human genetics; Matthew Brauer, Ph.D., vice president, data science; Jason Coloma, Ph.D., chief operating officer; Jeffrey Finer, M.D., Ph.D., chief technology officer; Eric Green, M.D., Ph.D., vice president, R and D David Morgans, Ph.D., senior vice president, drug discovery; and Tara Nickerson, Ph.D., chief business officer.
Third Rock Ventures is a leading healthcare venture firm focused on disruptive areas of science and medicine to discover, launch and build companies that make a dramatic difference in people's lives.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 1, 2019|
|Previous Article:||Mperia Therapeutics Names Weber to Clinical Advisory Board.|
|Next Article:||Innovus Pharma's BH Testosterone Booster Product in Canada for the Indication to Help to Support Testosterone Levels and Production in Adult Males.|